Presentations

Kaspar Rufibach, PhD
Biostatistician

Last updated: 2$^{\text{nd}}$ August, 2019

ORGANIZATION OF SEMINARS AND TOPIC CONTRIBUTED SESSIONS:

01/11/2019 Seminar of the Basel Biometrics Section, Basel, Switzerland. *Predictive modelling, machine learning and causality (jointly organized with Laurent Essioux, Dominik Heinzmann, Marcel Wolbers).*

10/05/2019 Spring seminar of the Basel Biometrics Section, Basel, Switzerland. *External controls - what do we need and how far can we go? (jointly organized with Hans Ulrich Burger, Dominik Heinzmann, Simon Wandel).*

18/10/2018 Roche Early Development Research and Diagnostics Summit, Munich, Germany. *Statistical Know-How for Innovative Clinical Concepts (jointly organized with Kerstin Trunzer).*

26/06/2018 Seminar of the Basel Biometrics Section, Basel, Switzerland. *RCTs, personalized medicine, and surrogacy (jointly organized with Dietrich Knoerzer).*

20/03/2018 Seminar of the Basel Biometrics Section, Basel, Switzerland. *Competing Risks and Multistate Models (jointly organized with Dietrich Knoerzer, Amanda Ross, Marc Vandemeulebroecke, Simon Wandel, Marcel Wolbers).*

13/09/2017 Roche European Biostatistics Conference, Welwyn, UK. *Network Meta Analysis - current challenges and the NICE perspective.*

23/08/2017 Conference of the Central European Network of the International Biometric Society, Vienna, Austria. *The assessment of probability of success for clinical trials (jointly organized with Hans Ulrich Burger and Marcel Wolbers).*

18/06/2015 Joint Meeting of the International Biometric Society Austro-Swiss and Italian Regions, Milan, Italy. *Adaptive clinical trials with subpopulation selection (jointly organized with Hans Ulrich Burger and Dominik Heinzmann).*

INVITED PRESENTATIONS:

16/10/2019 Clinical Trials Europe, Basel, Switzerland. *Implications of the ICH E9 estimand addendum on how we develop, run, and analyze clinical trials.*

10/09/2019 Conference of the Austro-Swiss Region of the IBS, Lausanne, Switzerland. *Before going BIG - seize opportunities for small data: use of multistate models to improve decision-making and effect quantification in clinical trials.*

04/07/2019 PSI webinar. **rpact** - *R Package for Adaptive Clinical Trials.*

27/06/2019 Shanghai Biostatistics Forum, Shanghai, China. *Multistate models to improve decision-making and effect quantification in clinical trials.*

23/05/2019 Bayesian Biostatistics Conference (bayes-pharma), Lyon, France. *Bayesian Predictive Power: Theory, challenges in implementation, and perspectives.*

10/05/2019	Spring seminar of the Basel Biometric Section, Basel, Switzerland. *External controls in drug development (with Hans Ulrich Burger).*
02/04/2019	SMi conference on adaptive clinical trials, London, UK. *MIRROS: Phase 3 trial with time-to-event endpoint, cure proportion, and futility interim analysis using response.*
22/11/2018	Statistics seminar, University of Bochum, Germany. *Univariate log-concave density estimation and more efficient treatment effect estimation in pre-specified subgroups displayed in forest plots for time-to-event outcomes.*
23/10/2018	Oncology workshop, University of Heidelberg, Germany. *MIRROS: Planning a Phase 3 trial with time-to-event endpoint, a cure proportion, and a futility interim analysis using response.*
18/10/2018	Roche RxDx summit, Munich, Germany. *Randomization and External Controls - When to Use What in a Drug Development Landscape.*
10/09/2018	Modeling and Simulation seminar, Basel, Switzerland. *Immortal bias - you live longer if you cannot die.*
21/06/2018	Biostatistics group Boehringer-Ingelheim, Biberach, Germany. *Overall survival prediction conditional on post-randomization events: multistate models, landmark analyses, and others.*
13/02/2018	Special Colloquia Epidemiology, Biostatistics, and Prevention Institute, University of Zurich, Zurich, Switzerland. *Estimands and the ICH E9 draft addendum.*
24/11/2017	Meeting of the Working Group Pharmaceutical Research of the German Region of the IBS, Freiburg, Germany. *Treatment effect measures for time-to-event endpoints - estimands, analysis strategies, and beyond.*
03/11/2017	Adaptive Clinical Trials Summit, Berlin, Germany (conference was cancelled). *MIRROS - a phase III trial with overall survival primary endpoint, a cure proportion, and a futility interim analysis using response and event-free survival.*
04/10/2017	2nd EFSPI Workshop on Regulatory Statistics, Basel, Switzerland. *Construction of an Estimand in a Clinical Trial on Progressive Multiple Sclerosis.*
31/08/2017	Joint Meeting of the International Biometric Society Austro-Swiss, German, and Polish Region, Vienna, Austria. *Evolvement of assurance over the lifecycle of several Phase 3 trials in a large oncology clinical development program.*
13/06/2017	Workshop on Innovation in Oncology Clinical Trial Design, organized by the Cancer Drug Development Forum (CDDF), Frankfurt. *Treatment effect measures for time-to-event endpoints - Estimands and beyond.*
13/03/2017	Seminar, Basel Biometric Section of the IBS, Basel. *Comparison of clinical development plans for a confirmatory trial with subpopulation selection.*
12/12/2016	Statistics Seminar, Institute for Medical Biometry, University of Heidelberg, Heidelberg. *Bayesian Predictive Power: update after a blinded interim analysis and choice of update after a blinded interim analysis and choice of prior.*
14/11/2016	European Statistical Forum, Berlin. *Estimands for time to event endpoints.*
10/11/2016	Statistics Seminar, Institute for Social and Preventive Medicine, University of Lausanne, Lausanne. *Bayesian Predictive Power: update after a blinded interim analysis and choice of prior.*
12/09/2016	EFSPI Regulatory Statistics Workshop, Basel. *Estimands for time to event endpoints in oncology and beyond (delivered by Uli Burger).*
24/05/2016	PSI conference, Berlin. *Time to think about estimands for time-to-event endpoints? A few examples (delivered by Uli Burger).*
28/04/2016	Seminar, Basel Biometric Section of the IBS, Basel. *Event projection: quantify uncertainty and manage expectations of broader teams.*

02/03/2016	Statistics Seminar, University of Ulm, Ulm. *Bayesian Predictive Power: Choice of Prior and some Recommendations for its Use as Probability of Success in Drug Development.*
20/11/2015	3rd BIMIT (Verbundprojekt "Biostatistische Methoden zur effizienten Evaluation von Individualisierten Therapien") workshop, Göttingen. *A Weibull Regression Model for a Time-to-Event Endpoint with an Interval-Censored Covariate and its Application in Assessing Prentice's Criteria for Surrogacy.*
27/10/2015	Seminar, Basel Biometric Section of the IBS, Basel. *Bayesian Predictive power: the bathtub phenomenon.*
18/06/2015	Joint Meeting of the International Biometric Society Austro-Swiss and Italian Regions, Milan, Italy. *Comparison of clinical development plans for a confirmatory trial with subpopulation selection.*
17/04/2015	Seminar, Institute for Mathematical Statistics and Actuarial Science, University of Bern, Switzerland. *Bayesian predictive power: update after a blinded interim & fallacies.*
20/11/2014	2nd BIMIT (Verbundprojekt "Biostatistische Methoden zur effizienten Evaluation von Individualisierten Therapien") workshop, Bremen. *How good is your biomarker? Comparison of development plans for confirmatory biomarker enrichment.*
11/11/2014	Joint DIA/AEMPS Statistics Workshop, Barcelona. *How good is your biomarker? Comparison of development plans for confirmatory biomarker enrichment.*
18/09/2014	2nd Symposium for the RxDx Generation, Roche, Penzberg. *How statistics can contribute to innovative trials.*
27/03/2014	University of Zurich / ETH applied statistics seminar, Zurich. *Update Bayesian predictive power after a blinded interim analysis.*
12/05/2010	Research Section Meeting Royal Statistical Society, London. *Proposal of the vote of thanks in discussion of Cule, M., Samworth, R., and Stewart, M.:Maximum likelihood estimation of a multidimensional logconcave density.*
26/01/2010	Workshop "Statistical Issues in Prediction: What can be Learned for Individualized Predictive Medicine?", Oberwolfach, Germany. *Score regression: a new approach to assess calibration of continuous probabilistic predictions.*
12/01/2010	Seminar, Basel Biometric Section of the IBS, Basel. *Ordered monotone regression.*
11/02/2009	Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Palo Alto, CA, USA. *Regularized regression models in R.*
17/01/2008	Seminar, Basel Biometric Section of the IBS, Basel. *A general criterion for multiscale inference.*
18/12/2007	Seminar, Institute for Stochastics, University of Karlsruhe, Germany. *Nonparametric Estimation of Log-Concave Densities.*
28/09/2007	Seminar, Institute for Mathematical Statistics and Actuarial Science, University of Bern, Switzerland. *A general criterion for multiscale inference.*
13/09/2007	Basel Institute for Clinical Epidemiology, University of Basel, Switzerland. *Predicting Alzheimer from proteomic blood markers.*
31/07/2007	Seminar, Statistics Department, Stanford University, United States. *Max-domain of attraction for log-concave densities and smooth tail index estimation.*
11/11/2006	Workshop "Qualitative Assumptions and Regularization in High-Dimensional Statistics", Oberwolfach, Germany. *The log-concave density estimator as a smoother.*
23/08/2005	Seminar, Statistics Department, Stanford University, United States. *Log-concave density estimation.*

Contributed conference presentations:

04/06/2019	PSI annual conference, London, UK. *Estimand framework in Oncology drug development – impact and opportunities.*
19/03/2019	Annual Meeting of the International Biometric Society, German Region, Munich, Germany. *Estimand framework in Oncology drug development – impact and opportunities (talk delivered by Björn Bornkamp).*
17/10/2018	Roche Global Biostatistics Conference, Madrid, Spain. *Assess Common Surrogate Endpoints in Lymphoma using a Multistate Model.*
04/10/2018	Workshop on Adaptive Designs and Multiple Testing Procedures, Bremen, Germany. *More efficient treatment effect estimation in pre-specified subgroups displayed in forest plots for time-to-event outcomes.*
28/03/2018	Annual Meeting of the International Biometric Society, German Region, Frankfurt, Germany. *The Estimand Framework Applied to Time-to-event Endpoints.*
12/07/2017	Annual Conference of the International Society for Clinical Biostatistics, Vigo, Spain. *Joint modelling of progression-free and overall survival.*
23/08/2016	Annual Conference of the International Society for Clinical Biostatistics, Birmingham, Great Britain. *Bayesian Predictive Power: Choice of Prior and some implications.*
24/05/2016	PSI annual conference, Berlin, Germany. *Bayesian Predictive Power: Choice of Prior and some Recommendations for its Use as Probability of Success in Drug Development (delivered by Markus Abt).*
16/06/2015	Joint Meeting of the International Biometric Society Austro-Swiss and Italian Regions, Milan, Italy. *Evaluation of possible designs for a three-arm clinical trial: Comparing a closed-testing design to potential alternatives.*
20/05/2015	Roche Global Biostatistics Conference, San Francisco, United States. *Evaluation of possible designs for a three-arm clinical trial: Comparing the CLL11 design to potential alternative designs.*
28/08/2014	Annual Conference of the International Society for Clinical Biostatistics, Vienna, Austria. *Weibull Regression for a Right-Censored Endpoint with a Censored Covariate.*
02/07/2014	Bayesian Biostatistics 2014 - Satellite conference of the International Biometric Conference, Zurich, Switzerland. *Update Bayesian predictive power after a blinded interim analysis.*
23/10/2013	Update Bayesian Predictive Power after a blinded interim analysis, Roche Global Biostatistics Conference, Brighton, United Kingdom.
13/09/2011	Conference of the Central European Network of the International Biometric Society (CEN 2011), Zurich, Switzerland. *A smooth ROC curve estimator based on log-concave density estimates.*
21/06/2011	Methods in Meta Analysis Meeting, London, UK. *Selection models with monotone weight functions in meta analysis.*
03/08/2010	Joint Statistical Meetings, Vancouver, Canada. *Ordered Monotone Regression.*
02/03/2010	German Open Conference on Probability and Stochastics, Leipzig, Germany. *Ordered Monotone Regression.*
12/03/2008	Conference of the Central European Network of the International Biometric Society (Lifestat 2008), Munich, Germany. *On a new approach to regression models with ordinal explanatory variables.*
11/09/2007	ROeS Seminar 2007, Bern, Switzerland. *On a new approach to regression with ordered explanatory variables.*
15/03/2006	German Open Conference on Probability and Stochastics, Frankfurt, Germany. *Smoothed semi-parametric tail index estimation and max-domain of attraction for log-concave densities.*
27/07/2005	European Meetings of Statisticians, Oslo, Norway. *Log-concave density estimation.*

19/07/2005	European Young Statisticians Training Camp, Oslo, Norway. *Log-concave density estimation and bump hunting.*
26/03/2004	German Open Conference on Probability and Stochastics, Karlsruhe, Germany. *Log-concave density estimation and uniform rate of convergence.*
06/08/2003	Joint Statistical Meetings, San Francisco, United States. *Computing maximum likelihood estimators of log-concave densities.*

INTERNAL METHODOLOGICAL PRESENTATIONS:

27/06/2019	MIRROS: Planning a Phase 3 trial with time-to-event endpoint, a cure proportion, and a futility interim analysis using response (Roche Biostatistics Department, Shanghai).
18/03/2019	To explain or to predict - what is the difference? And how to plan a prediction model? (Biostatistics workshop, Department of Biostatistics, Basel).
27/02/2019	To be fast or to be sure? Trade-offs in drug development (Roche Early Development and Research (pRED) Science@Site Lecture Series, Basel).
30/01/2019	MIRROS: Planning a Phase 3 trial with time-to-event endpoint, a cure proportion, and a futility interim analysis using response (Roche Biostatistics Department, Welwyn).
16/07/2018	Extract more information from a clinical trial than just Kaplan-Meier estimates of the primary endpoint: a case study in multistate modeling (Biostatistics workshop, Department of Biostatistics, Basel).
09/10/2017	Quantification of follow-up for a time-to-event endpoint (Biostatistics workshop, Department of Biostatistics, Basel).
20/09/2017	Joint modelling of progression-free and overall survival (Seminar, Roche Germany Biostatistics and Epidemiology Group, Grenzach).
13/09/2017	Estimands - a refinement of ITT (jointly with Chris Harbron, Roche Basel - Welwyn - Shanghai Biostatistics Conference, Welwyn).
23/05/2017	Estimands – current ICH E9 working group proposal (jointly with Chris Harbron, Genentech North America Biostatistics Seminar, South San Francisco).
19/12/2016	Estimands – do you know what you are estimating? (Roche HTA group, Basel).
24/11/2016	Compare Phase 3 with futility interim to randomized Phase 2 + Phase 3 and single-arm Phase 2 + Phase 3 (Roche Statistics Workshop, Welwyn).
25/09/2016	Immortal time bias and post-randomization variables (jointly with Marcel Wolbers, Roche Statistics Workshop, Basel).
11/05/2016	Bayesian Predictive Power - Choice of Prior (Genentech North-American Biostatstics Forum, South San Francisco).
15/10/2015	Estimands – do you know what you are estimating? (Roche Basel & Welwyn Joint Biostatistics Seminar, Welwyn).
29/09/2015	Hierarchical testing of a secondary endpoint in a group-sequential design (Roche Statistics Workshop, Welwyn).
17/08/2015	Bayesian Predictive power: the bathtub phenomenon (Roche Statistics Workshop, Basel).
16/02/2015	Hierarchical testing of a secondary endpoint in a group-sequential design (Roche Statistics Workshop, Basel).
20/08/2014	Estimation of a survival curve beyond where we have data, with application to event tracking for time-to-event outcomes (Health Economics Department, Roche Basel).
11/08/2014	Event tracking for time-to-event outcomes (Roche Asia Pacific Biostatistics Workshop).

24/07/2014	Statistical MythBusters (Roche Oncology Forum, Basel).
16/06/2014	Event tracking for time-to-event outcomes (Roche Statistics Workshop, Basel).
17/12/2013	Immortal bias - or why it is a bad idea to plot a time-to-event endpoint by response category (Roche Statistics & Oncology Forum, Shanghai).
06/11/2013	Some examples for R and Sweave applications (Roche Statistical Programming Workshop, Basel).
02/09/2013	Immortal bias - or why it is a bad idea to plot a time-to-event endpoint by response category (Roche Biostatistics Basel/Welwyn/Shanghai Meeting, Basel).
04/02/2013	Probability of technical success: Conditional Power, Bayesian Predictive Power, or Bayesian Updating? (Roche Biostatistics Basel/Welwyn/Shanghai Meeting, Basel).
17/12/2012	Writing R packages and use of Sweave (Roche Statistics Workshop, Basel).
30/11/2012	Probability of technical success - two ways of looking at it (Roche pRED Meeting, Basel/Nutley).
19/11/2012	Unbiased estimation of a proportion after a 2-stage trial (Roche Statistics Workshop, Basel).
12/07/2012	A new smooth ROC curve estimate based on log-concave densities (Roche Biostat Biomarker Community Meeting, Basel).
27/01/2011	Categorization of continuous covariates (Zurich).
03/12/2009	p-values in high-dimensional regression (Zurich).
04/06/2009	Estimation and computation of the median for right-censored data (Zurich).
12/01/2009	Consulting and reproducible research (Zurich).
06/11/2008	Exact logistic regression (Zurich).
06/03/2008	L_1 and Least angle regression (Zurich).
06/12/2007	On a new approach to regression with ordinary explanatory variables (Zurich).
25/01/2006	Semi-parametric tail index estimation and max-domain of attraction for log-concave densities (Bern).
04/05/2005	Local asymptotic normality and Le Cam's third lemma (Bern).
11/01/2005	Penalized estimators (Bern).
01/12/2004	Asymptotics for Lasso-Type Estimators (Bern).
28/04/2004	Estimation of a Proportion in Group Sequential Trials (Bern).
26/11/2003	Density Estimation under Qualitative Assumptions (Bern).
07/01/2003	Convex Programming (Bern).